vs
Side-by-side financial comparison of FEDERAL AGRICULTURAL MORTGAGE CORP (AGM) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $107.5M, roughly 1.7× FEDERAL AGRICULTURAL MORTGAGE CORP). On growth, FEDERAL AGRICULTURAL MORTGAGE CORP posted the faster year-over-year revenue change (6.1% vs 5.0%). Over the past eight quarters, FEDERAL AGRICULTURAL MORTGAGE CORP's revenue compounded faster (7.1% CAGR vs -0.2%).
The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
AGM vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $107.5M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 6.1% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $3.69 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $107.5M | $196.9M | ||
| Q3 25 | $104.0M | $179.5M | ||
| Q2 25 | $102.6M | $181.1M | ||
| Q1 25 | $94.3M | $168.9M | ||
| Q4 24 | $101.3M | $187.3M | ||
| Q3 24 | $90.3M | $168.6M | ||
| Q2 24 | $89.9M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | $5.4M | ||
| Q2 25 | $54.8M | $-4.8M | ||
| Q1 25 | $49.7M | $4.8M | ||
| Q4 24 | $56.5M | — | ||
| Q3 24 | $49.8M | $-143.5M | ||
| Q2 24 | $47.1M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 56.3% | 1.2% | ||
| Q3 25 | 64.1% | 3.5% | ||
| Q2 25 | 63.8% | 4.7% | ||
| Q1 25 | 66.9% | 1.2% | ||
| Q4 24 | 67.5% | 13.2% | ||
| Q3 24 | 69.0% | -82.8% | ||
| Q2 24 | 65.9% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | 52.9% | 3.0% | ||
| Q2 25 | 53.4% | -2.7% | ||
| Q1 25 | 52.6% | 2.8% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | 55.2% | -85.1% | ||
| Q2 24 | 52.4% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $3.69 | $0.05 | ||
| Q3 25 | $4.44 | $0.12 | ||
| Q2 25 | $4.48 | $-0.11 | ||
| Q1 25 | $4.01 | $0.10 | ||
| Q4 24 | $4.62 | $0.38 | ||
| Q3 24 | $3.86 | $-3.11 | ||
| Q2 24 | $3.68 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $30.8B | — |
| Stockholders' EquityBook value | $1.7B | $653.9M |
| Total Assets | $35.4B | $1.2B |
| Debt / EquityLower = less leverage | 17.93× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | $842.1M | $453.8M | ||
| Q2 24 | $923.0M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $30.8B | $372.2M | ||
| Q3 25 | $29.2B | $376.7M | ||
| Q2 25 | $28.9B | $580.5M | ||
| Q1 25 | $28.0B | $583.4M | ||
| Q4 24 | $27.5B | $585.3M | ||
| Q3 24 | $27.2B | — | ||
| Q2 24 | $26.8B | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.7B | $693.1M | ||
| Q3 25 | $1.7B | $727.2M | ||
| Q2 25 | $1.5B | $757.8M | ||
| Q1 25 | $1.5B | $798.5M | ||
| Q4 24 | $1.5B | $778.3M | ||
| Q3 24 | $1.5B | $749.6M | ||
| Q2 24 | $1.5B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $35.4B | $1.3B | ||
| Q3 25 | $33.4B | $1.3B | ||
| Q2 25 | $33.0B | $1.5B | ||
| Q1 25 | $31.8B | $1.6B | ||
| Q4 24 | $31.3B | $1.6B | ||
| Q3 24 | $30.6B | $1.5B | ||
| Q2 24 | $30.2B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 17.93× | 0.54× | ||
| Q3 25 | 17.31× | 0.52× | ||
| Q2 25 | 18.70× | 0.77× | ||
| Q1 25 | 18.39× | 0.73× | ||
| Q4 24 | 18.48× | 0.75× | ||
| Q3 24 | 18.60× | — | ||
| Q2 24 | 17.87× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $80.1M | $43.7M | ||
| Q3 25 | $74.2M | $60.8M | ||
| Q2 25 | $-47.7M | $12.0M | ||
| Q1 25 | $-49.8M | $35.5M | ||
| Q4 24 | $612.6M | $33.1M | ||
| Q3 24 | $-44.4M | $53.9M | ||
| Q2 24 | $56.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | $607.4M | $31.0M | ||
| Q3 24 | $-44.4M | $49.8M | ||
| Q2 24 | $52.6M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | 599.8% | 16.6% | ||
| Q3 24 | -49.2% | 29.6% | ||
| Q2 24 | 58.5% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 5.1% | ||
| Q4 24 | 5.2% | 1.1% | ||
| Q3 24 | 0.1% | 2.4% | ||
| Q2 24 | 4.0% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.35× | 11.20× | ||
| Q2 25 | -0.87× | — | ||
| Q1 25 | -1.00× | 7.37× | ||
| Q4 24 | 10.84× | — | ||
| Q3 24 | -0.89× | — | ||
| Q2 24 | 1.19× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGM
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
